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In recent years, nearly 80,000 aortic valve replacements (AVRs) have been performed annually in the United States 1 in an increasingly older and sicker patient population. 2 Among older patients, bioprostheses are an attractive alternative to the more thrombogenic mechanical prostheses; [3] [4] [5] however, data regarding the long-term safety and effectiveness of biologic versus mechanical prostheses among elderly AVR patients is limited. Most clinical trial data 6, 7 are now three decades old and no longer reflect the current state of technology, nor the population characteristics encountered in clinical practice. Furthermore, observational analyses have been limited, lacking both: (1) clinical and procedural details necessary for accurate treatment assignment and risk-adjustment; 8 and (2) sufficient power and generalizability to provide reliable comparisons. 9, 10 In response to the need for better data on the relative safety and effectiveness of aortic valve prostheses in older patients, we identified a cohort of Medicare-linked AVR patients within the Society of Thoracic Surgeons Adult Cardiac Surgery Database (STS ACSD). Using this cohort, we sought to: (1) evaluate long-term mortality and valve-related complications in older individuals treated with bioprosthetic versus mechanical aortic valves; and (2) examine the consistency of these findings among strata of commonly encountered patient subgroups.
Methods
Since 1991, the STS ACSD has collected detailed in-hospital data on adult patients undergoing cardiac surgery with the aim of improving quality of care and post-operative outcomes, 11 with more than 1,000 currently participating institutions throughout the United States.
For the purposes of this study, we identified a cohort of Medicare-linked fee-for-service (FFS) patients between 65 and 80 years of age undergoing elective or urgent AVR with a mechanical or comparisons. 9, 10 In response to the need for better data on the relative safety and effectiveness of aortic va alv lv ve e p pr pros os sth th the eses s i i in n n ol o der patients, we identified a a a c co ohort of Medic ic car a e--li li lin n n d k ked AVR patients within h h he S Society of f T Tho ho hora aci ci cic Su S Surg rg rgeo eo ons ns A A Adu dult lt Car rdi diac S S Su ur rge e ery ry ry D D Dat atab aba a ase e e
(S (STS T T A ACS CS CSD) D). Us Us Usin in i g g th th this is
co oho ho h rt rt rt, , we we s s so ou ough gh ht to to: : ( (1) ) ) ev e al al alua ua ate te te l l lo on ong g-g-te te erm rm rm m m mor or o t ta tal li ity ty y and nd nd v val al alve ve v -r -rel el elat at a e e ed c com om mpl pl plic icat at atio io ions s s in n n ol olde de der r ndividuals tr trea ea eate te t 
Follow-up Information
To obtain follow-up information on the study cohort, we linked de-identified STS patient records with research-identifiable Medicare inpatient standard analytic claims files through December 31, 2007, by using combinations of indirect identifiers including age, sex, and dates of birth, admission, and discharge (linkage rate, 76.8%). 12 Institutional Review Board granted a waiver of informed consent and authorization for this study.
Clinical Endpoints
The primary endpoint was all-cause mortality, identified using the Medicare denominator file.
Secondary endpoints were identified using primary hospital diagnosis International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes and with research-identifiable Medicare inpatient standard analytic claims files throug ug gh h De Dece ce cemb mb mber er 31, 2007, by using combinations of indirect identifiers including age, sex, and dates of birth, ad dmi mi miss ss ssio io ion, n n, a an n nd d d dis is isch charge (linkage rate, 76.8%). 12 12 12 C C Compared with h p patie ie ent nt nts s in the Medicare-linked pop pu pulation, el lig igib ib i l le e p pa a atie ie ent nt nts s w w wh ho ho w w we er ere e n no ot li i ink k ked w were e e o on on a a ave e er rag ag ge e sl slig ight ht h ly ly y y you oung nge er e ( ( (75 75 75 v v vs s. s. 7 7 76 ye year ar ars) s) s), , le less ss s o o of ft ften en n f f fem em e a a ale e e (3 (39. 9 0% 0% 0% v v vs. s. s. 4 40 0 0.8% 8% 8%) ), ), les es ess s o of ft ften n n C C Cau au auca ca asi si sian an n ( ( (86 86 86.2 .2 2% % % vs vs s. . 92 92 9 .1 .1 1%) % %), , l l les ss ss o of f fte en n undergoing e ele le lect ct c iv iv ve e e pr pr proc oc o ed d dur ur ures es ( ( (73 73 7 . .4% 4% 4% v v vs. s. s 7 7 75. 5. 5 5% 5% 5%), ), ), a a and nd d l l les es ess s li li ike ke kely l l t t to o o re re rece ce ceiv iv ve e bi bi b ol ol olog og ogic ic ic prostheses s s included rehospitalization for aortic valve reoperation, cerebrovascular accident (CVA), hemorrhagic CVA, hemorrhage, and endocarditis as identified using ICD-9-CM codes (Supplemental Appendix 1). Temporal trends in the use of bioprosthetic valves in the aortic position among 65 to 80 year old patients in the overall STS ACSD and the Medicare-linked cohort from 1991 to 1999
Statistical Analysis
were calculated as a function of the total AVR volume to account for the increasing penetrance of the database across this timeframe. The frequency of the specific valve prostheses used in this cohort are presented in Supplemental Table 1 .
Patients receiving biologic and mechanical aortic prostheses were compared using propensity scores with inverse probability-weighting (IPW) to adjust for differences in baseline characteristics between the two treatment groups. The propensity score represents the estimated probability of patients receiving a biologic (vs. mechanical) prosthesis as a function of the covariates in the propensity model. 13 Propensity scores were estimated using a non-parsimonious logistic regression model, including each of the variables listed in Supplemental Appendix 2.
The propensity model included interactions between the year of surgery and each of the other was used to compare continuous variable distributions. SAS statistical software (v (v ver er rsi si ion on 9 9 9.1 .1 .1; ; SAS Institute, Cary, NC) was used for all calculations. we we ere re r c c cal al a cu cu ula la late t ted d a as as a a f fun un unct ctio i n n n of of f t t the he he t tot ot tal al l A A AVR VR VR vo vo volu lu ume me e t to o o a ac acco co oun un unt fo fo for r t th the e in inc cr crea ea easi sing ng ng p pe e ene et etra ran nc nce e of the databas as se e e ac ac acro ro ross ss s t thi h h s ti ti t me me m fr fr fram am ame. e e T T The he he f f fre re requ qu quen en ency cy cy o of f f th th the e e sp sp spec ec ecif i i ic c c v v val al alve ve ve p p pr ros os sth th hes es eses es es u used in this s s variables in the model. To account for changes in data definitions and quality over the study period, we estimated a separate set of regression coefficients for each calendar year. or >96.43%) were omitted from the risk-adjusted analysis. Next, we compared the distribution of patient characteristics across the two treatment groups before and after propensity score weighting; the observed differences in covariates were small, and in all cases were less than 5% of the estimated standard deviation. indicator and weighting each observation by the inverse of the estimated propensity score. 15 The association between valve type and each non-fatal endpoint was analyzed by modeling the causespecific hazard function in each treatment group. Specifically, we assumed that the causepropensity scores that were not in the range of overlapping propensity di f stribution on ns s ( (i.e .e e., , , < < <6. 6. 6.20 2 20%
or >96.43%) were omitted from the risk-adjusted analysis. Next, we compared the distribution of pa ati ti ien en ent t t ch ch char ar arac ac cteri ri rist st stic ics across the two treatment gr gr grou ou ups before and d af a te er r r p pr propensity score w wei ig ghting; the e o obs bs bser rv ve ed d di di diff ff ffer er eren ence ce es s s in in c co ovar ar ria a ates w w were e e s s sma ma all l, , an an nd d in in a all l l c c cas ase es es w wer er re e e le le less ss s t tha ha han n n 5 5% % of f f t t the he he e e est stim im mat at ated ed sta ta and ndar ard d d de dev vi viat at atio io ion. n. n. 14 14 The ti time me me-t -t to-o-o ev ev even en nt an an anal al a ys ys ysis is is a a ass s s um um umes es e n n non on on-i -i inf nf nfor or orma ma ati ti t ve ve ve c cen en enso s s ri ri ring ng ng. . Pa Pa Pati ti tien en nt t t fo fo foll ll llow ow ow-up was specific hazard functions were proportional. This methodology was equivalent to fitting a standard Cox model and treating mortality as a censoring variable. The proportional hazards (PH) assumption was evaluated for each outcome using visual inspection of both cumulative hazards plots and log cumulative hazards plots. By visual inspection, the PH assumption was satisfied for stroke, bleeding, and endocarditis. For aortic valve reoperation, the PH assumption was less clearly satisfied; however, we elected to present a single combined estimate for this outcome because the treatment effect is in the same direction over time without overlap of the hazards function. For mortality, survival curves clearly violated the PH assumption (with overlap shown in Figure 1 ). Therefore, for this endpoint, we have presented time-dependent HRs for each of three time periods, corresponding to early follow-up (0-3 months), mid-term follow-up (3mo-9 years), and late follow-up (>9 years). Robust sandwich variance estimates 16 were used to obtain 95% confidence intervals (CIs) of coefficients.
The unadjusted cumulative incidence of mortality was estimated for each treatment group using the product-limit method of Kaplan & Meier; 17 the propensity-adjusted incidence of mortality was calculated for each treatment group using the Breslow estimator 18 based on the IPW Cox model. A similar approach was also used for the aortic valve repair or replacement endpoint. The cumulative incidence rate for other non-fatal rehospitalization endpoints was analyzed using competing risk methods of Kalbfleisch & Prentice to account for the role of death in preventing subsequent hospitalizations. 19 For hemorrhage, hemorrhagic stroke, stroke, congestive heart failure (CHF), and endocarditis, our analyses focused on estimating the actual probability of the event (i.e., the probability that it will occur before a patient dies); whereas analyses of aortic valve repair or replacement focused on estimating the probability of valve failure in a death-free environment. 20, 21 each of three time periods, corresponding to early follow-up (0-3 months), mid--t te term m m f f fo ol ollo lo low-w-w-up up a 3mo-9 years), and late follow-up (>9 years). Robust sandwich variance estimates 16 were used to ob bta ta ain in in 9 9 95% 5% 5% co onfi fi fid de den nce intervals (CIs) of coeffic c ci ie ien nt ts.
The un nad ad adju u ust ted ed e c c cum um mul u ula at ativ ive e e in in i c ci id dence e o o of m m mo or rtal li lit ty ty w w wa as s e es s sti im mat ate ed e for or r e e eac ach h tr tr t e ea eatm tm me en ent t g gr gro ou o p us usin in ing g g th th the e pr pr prod od o uc uc ct t-l li limi mi it m me meth hod od od o o of f f Ka Ka K pl pl plan an an & & & M M Mei ei e e e er; ; 17 1 th th t e e e pr pr prop p pen en e si sity ty ty-a -a -d d dju us uste te ed d d in in inci ci ide de denc ce e e o of of mortality wa as s ca ca calc lc cul ul ulat at ted ed ed f for or or e e eac c ch h h tr trea ea e tm m men en ent t t gr gr grou ou o p p p us us usin ing g g th th the e e Br Br Bres es eslo low w w es es esti ti tima ma mato tor r r 18 18 18 b b bas as a ed ed e on the
The cumulative incidence of adverse events is reported at 12 years in the primary manuscript text; however, the cumulative incidence for each endpoint is reported annually through 15 years of follow-up in Supplemental Table 2 to facilitate comparisons with other available studies. Hazards ratios represent data from the full follow-up interval.
Analysis of Missing Data
Missing data in the baseline characteristics (used for adjusted analyses) were handled by multiple imputations under the assumption of missing at random (MAR). The multiple imputation procedure was performed using R software (www.R-project.org) with the add-on library package
Multivariate Imputation by Chained Equations (MICE). This package generates multiple imputations for incomplete multivariate data by Gibbs sampling. 22 Imputation was performed separately for each calender year using the covariates from the propensity model plus valve type, pre-op digitalis, pre-op diuretic, or pre-op beta blocker. Ten complete imputed datasets were created. The standard analyses, including the baseline characteristic summary statistics and the risk-adjusted analyses (described above), were performed separately for each of the completed datasets. The ten sets of results were then combined using the method proposed by Rubin.
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Subgroup Analyses
Prospectively derived subgroups were identified using STS data files, including: age (65-69, 70-74, and 75-80 years), sex, preoperative left ventricular ejection fraction (LVEF; <50%, 50%), and pre-operative renal function. Consistent with STS ACSD data definitions, renal failure was defined as a serum creatinine >2.0 mg/dl or dialysis. The IPW Cox model was applied within each strata of these four pre-specified groups to estimate strata-specific treatment effects.
mputations for incomplete multivariate data by Gibbs sampling. 22 Imputation wa wa as pe p p rf rf rfor r orme me med d d eparately for each calender year using the covariates from the propensity model plus valve type, pr re-e-op op op d d dig ig igit it ital al alis, pr pr pre-e-op diuretic, or pre-op beta b b bl lo loc cker. Ten com mpl pl p ete e im im impu p ted datasets were cr rea a at ted. The s sta tand nd n ar ard d d an an nal al alys ys yses es es, in in ncl cl clud ud u in ing g th he e b b base e eli in ne c ch ha hara ra ac ct ter eri is st ti ic su u umm mmar ar ary y y st stat at atis isti ti t cs cs s a a and n nd t t th he he i isk sk sk-a -a adj dj djus uste te ed d d an ana a aly ys yses es s (d de des scri ri ribe be ed d d ab ab abov ov ve) e) e), , we we were e e pe pe erf rf fo orme me med d d s se sepa pa para ra ate e ely ly ly f fo o or e eac ac ch h h of of o t t the he he com om ompl pl p et et ted d d
datasets. The e te te ten n n se se sets ts t o o of f f re esu su sult lt l s we we were re e the he hen n n co co omb mb mbin in ned ed e u usi ing ng ng t t the he h m m met e e ho ho hod d d pr pr prop op opos os o ed ed ed b b by y y Ru Ru R bin. 23 23 23 Results
Population Characteristics
The I In Intr tr tra-a a o oper er ra at ativ i e characteristics were simil l lar ar a f for bioprosthe eti ti t c ve vers rs rsu u us mechanical valve pati i ien e ts, with a a s s sim m mil il la ar ar p p pro ro opo po port rt rtio ion n n o of of p p pat t tient t ts u und de er r rgoi i in ng ng e ele lect ctiv iv ve pr proc oced d dur ure es es ( (82 82 2.5 .5 . % % % v v vs. . 82 82 82.8 . % %) % an nd d d a a a si si s mi mila la lar r r me mean an n t tim im me e on on c ca ar a di di diop op opu ul ulmo mo mona na nary ry ry by by byp pa pas ss s ( (13 13 32 2. 2.9 9 9 vs vs vs. . 1 13 132. 2 2.3 3 3 m mi minu nu n te te tes) s) ). . Bi Bi Bio op opro o ost the he h ti ti ic valve patients ts s w w wer er re e e mo mo more re r l lik ik ikel el e y y to to to u u und nd n er er ergo go go c c con on onco co comi mi mita ta t nt nt t C C CAB AB ABG G G su su s rg rg rger er ery y y (6 (6 (60. 0 0 1% 1% % v v vs. s. s. 5 5 55. 5 2%) and experienced a similar long-term mortality rate compared with mechanical valve patients (adjusted HR 1.04; 95% CI 1.01-1.07; Figure 1) . However, mortality rates were higher beyond 9 years of follow-up in patients treated with bioprosthetic than mechanical valves (Figures 1 and   4 ), a result that differed significantly from earlier time periods (p<0.002, comparing the adjusted HR in late follow-up vs. either early or mid-term follow-up).
The absolute risk of long-term mortality varied widely across patient subgroups and was particularly high among patients with either pre-operative renal failure (12-year mortality, 65.2%) or reduced LVEF (12-year, 74.1%; Figure 4 ). (Figure 4 ).
Aortic Valve Reoperation
The incidence of aortic valve reoperation was higher among bioprosthetic than mechanical valve patients throughout follow-up (unadjusted HR 1.91; 95% CI 1.64-2.22). By 12 years, reoperation was observed in 5.2% of bioprosthetic valve and 2.3% of mechanical valve patients.
Among the youngest patients (65-69 years), the incidence of bioprosthetic valve reoperation was 10.5%, which was more than three times the incidence observed among the oldest patients (75-80 years, 2.9%; Figure 5 ). Following risk-adjustment, bioprosthetic valves were associated with more than a two-fold increase in the long-term rate of reoperation compared with mechanical valves in the overall population (adjusted HR 2.55; 95% CI 2.14-3.03; Figure 1 ) and across Fi Figu gu ur re 4) ).
Ao Ao ort rt rtic ic ic V V Val al lve ve ve R Re eo eope pe per ra at ti ion on
The incidenc ce e e of of o a a aor or orti ti ic c c va valv lv lve e e re re eop op oper er rat a a io io on n n wa wa was s s hi hi h gh gh gher er r a amo mo mong ng ng b b bio io iopr p p os os osth th het et etic ic ic t t tha ha h n n n me me mech ch chan a ical valve e e most patient subgroups. This effect was larger among younger (compared with older) patients (pinteraction <0.05), but was similar across strata of other subgroups of interest.
Stroke
The 12-year incidence of stroke (all-cause) requiring rehospitalization was high among patients receiving either bioprosthetic or mechanical aortic valves (13.8% vs. 14.7%; unadjusted HR 1.00; 95% CI 0.95-1.06). After adjusting for baseline risk, the rate of stroke was significantly lower among bioprosthetic than mechanical valve patients in the overall cohort (adjusted HR 0.87; 95% CI 0.82-0.93) and in most of the pre-specified subgroups (Supplemental Figure 1) . Figures 2 and 3) .
Bleeding
Endocarditis
The 12-year incidence of rehospitalization for endocarditis was 2.2% for bioprosthetic valve and 
Discussion
This study provides a contemporary view of long-term outcomes with biologic versus mechanical prostheses for AVR in older individuals in the United States. Several important findings stem from these results. Although overall mortality was similar between bioprosthetic and mechanical valve patients, mechanical valves were generally associated with a lower riskadjusted mortality rate beyond 9 years. The incidence of aortic valve reoperation was substantially higher among bioprosthetic than mechanical valve patients, and this difference was especially pronounced among the youngest AVR patients (65-69 years) in whom the observed 12-year bioprosthetic valve reoperative rate reached 10.5%. Finally, rehospitalization for both bleeding and stroke was higher among patients with mechanical aortic valves, although endocarditis was more common among bioprosthetic valve patients. These data highlight the complexity of selecting an appropriate prosthesis in elderly patients undergoing AVR.
Mortality
The 12-year incidence of mortality (66.5%) was high in this older Medicare-linked AVR cohort.
This risk was age-dependent, ranging from 53% among 65 to 69 year-olds to 77% among those 75 to 80 years old. Direct comparison with clinical trial results is limited by the substantially younger age of patients tested in the Edinburgh (1975-1979; mean age, 54 years) 7 and Veterans
Affairs Cooperative (1977-1982; mean age, 59 years) 6 studies; however, the decision analysis of Birkmeyer et al. 24 does provide some insight. Based on a pooled analysis of the Edinburg and Veterans Affairs Cooperative study data, Birkmeyer et al. reported 12-year mortality estimates of ubstantially higher among bioprosthetic than mechanical valve patients, and thi is s s di di iff ff fer er eren en ence ce ce w was especially pronounced among the youngest AVR patients (65-69 years) in whom the observed 12 2-y -y -yea ea ar r r bi bi biop op opr r rost the he heti tic valve reoperative rate reac c ch h hed d d 10.5%. Final ally ly l , re re eho ho hospitalization for both b bl lee e edi d ng and s str trok ok oke w wa was s hi hi high gh ghe er er a amo mo mong ng g p p patie ent t ts w wi ith h h m m mec ec cha ha ani ni ica cal l ao ort rtic ic v val alve ve es s, s, a alt lt tho ho houg ug u h h h en ndo do d ca ca card rdit itis is is w was as s m m mor ore e e c co comm mm mon on n a a am m mon ong g g bi bi biop op opro o ost st s h he het ti ic c va va valv lv lve e e pa pa ati ti t e en ent t ts s. s. T The he hese se d d dat at ta a a hi hi high gh ghli igh gh ght t th the e e complexity o of f f se se ele le ect ct ctin in ng g an n a a app pp p ro ro ropr pr p ia ia iate te p p pr r ros os osth th thes es esis is s i in n n el el e de de erl rl rly y y pa pa pati ti tien en e ts ts s u u und nd nder er ergo go goin in ng g g AV AV AVR. R R 62% for patients 70 years of age. These results are nearly identical to those observed in the STS Medicare-linked cohort (70-74 year olds, 64%), suggesting very little improvement in long-term patient outcomes following AVR from the 1970s to 1990s. Nevertheless, caution should be used in the interpretation of these data, as previous work has demonstrated that both: (1) the burden of comorbidities in patients undergoing AVR has increased over time; 2 and (2) long-term mortality following AVR is more closely related to complications associated with patient comorbidities than with prosthesis failure. 6 In the overall study cohort, long-term mortality rates were similar across prostheses (HR 1.04); however, the prosthesis-associated relative risk varied across patient subgroups and over the duration of follow-up. For example, among the youngest patients (65 to 69 years of age), mechanical valves were associated with a 23% relative reduction in the risk-adjusted long-term mortality rate when compared with bioprostheses; however, this benefit was not observed among patients 70 to 80 years of age. Additionally, among patients surviving to 9 years after AVR, bioprosthetic valves were associated with a significantly higher mortality rate in the overall cohort and among most patient subgroups. This finding is consistent with those of both the Veterans Affairs Cooperative study and the Edinburgh trial 7 which reported a late (10 to 15 year) increase in excess mortality among bioprosthetic valve patients.
Aortic Valve Reoperation
Valve degeneration remains an important concern in the selection of appropriate aortic valve prosthesis. In this older cohort, the 12-year incidence of bioprosthetic aortic valve reoperation (4.0%) was substantially lower than that reported from either the Edinburgh study 7 (11.3% at 10 years) or the Veterans Affairs Cooperative study 6 (29% at 15 years). While this risk was similar across most subgroups, the 12-year incidence of aortic valve reoperation in our study was he duration of follow-up. For example, among the youngest patients (65 to 69 ye ye ear r rs s s of of of a a age ge ge), ), ), mechanical valves were associated with a 23% relative reduction in the risk-adjusted long-term mo mort rt rtal al alit it ity y ra ra rate te te w whe he hen n n compared with bioprostheses es es; ; h h however, this be be b ne efi fi fit t t w w was not observed among pati i ien e ts 70 to 8 80 0 0 y year ars s s of of of a a age ge ge. . Ad Addi di diti ti t o on na a ally, , a am mon n ng g pa at ti tie en ents ts s s s sur urv v viv vi ving ng t to o 9 9 y ye year ars s af af a te te ter r AV AV AVR R, R, bi iop op opro ro rost st s he heti ti tic c c va val lv lve es es w w wer er re e as asso so s ci ci ciat at ated ed ed w w wit it th h h a a a sign gn gnif if fic can ant tl t y y y hi hi high gh gher er e m m mor or orta ta t l l lity y y r rat at ate e in in i t t the he he ov ve ver ra rall ll cohort and a amo mo mong ng ng m m mos os st t pa pa ati ti tien en ent su su subg bg gro r up up ups s. s. T T Thi hi h s s s fi fi f nd nd ndin in i g g is is i c c con on onsi si sist st s en n nt t t w w wit it ith h h th th thos os se e e of of of b b bot ot o h the substantially higher among the youngest (65-69 years) bioprosthetic valve patients (10.5% at 12 years)-a result which is consistent with previous randomized 6 and observational 25 data. In keeping with prior recommendations, 20, 21 this estimate is based on the probability of valve failure in a "death-free" environment (i.e., "actuarial probability"). As a result, reoperative rates described here approximate valve durability, with limited influence by patient survival. In other words, the high-risk of reoperation observed among the youngest patients is not explained by the expectation that these patients will live longer (and, therefore, have more time at risk) than the older patients. Nevertheless, two alternative explanations remain. First, the durability of bioprosthetic valves may truly be reduced in younger patients, 26 perhaps as a function of differences in calcium metabolism or increased mechanical stress inflicted on the valve by a more active, younger cohort. 27 Alternatively, this finding may be due in part to a referral bias favoring reoperation among younger patients with a lower expected operative risk. 28 Compared with mechanical valve patients, those receiving bioprostheses experienced a significantly higher risk for reoperation (HR 2.55)-a result which persisted across the spectrum of patient age. Unlike prior studies, this difference was observed throughout the follow-up interval; however, similar to previous reports, this difference appeared to accelerate beyond seven to eight years of follow-up.
Stroke and Bleeding
The risk of rehospitalization for either stroke or bleeding was high in this elderly cohort.
Offsetting the late survival and durability advantages of mechanical valves, both stroke and bleeding were less common among bioprosthetic valve patients. For example, in the overall cohort, bioprostheses were associated with a 13% relative reduction in the risk of stroke. While the absolute magnitude of this risk is consistent with prior analyses, 6,7 randomized comparisons differences in calcium metabolism or increased mechanical stress inflicted on the he e v val al a ve ve e b b by y y a a a more active, younger cohort. 27 Alternatively, this finding may be due in part to a referral bias fa avo vo ori ri rin ng ng r r reo eo eop p pera ati ti tio on on among younger patients wi i ith th th a a lower expect ted e e o ope pe per ra rative risk. 28 Compar are ed e w wit i ith h me me mech ch chan an anic ical al a v v va al lv ve e pa a atie e ents s, , t th hos s se e re rec ce ceiv ivin in ng g bi biop op pro o os sth th hes eses es e e exp xp per erie ien nc nced ed ed a a a i ign gn gnif if fic ic ican antl tl ly y y hi high gh ghe er er r ri is sk k fo for re re reop op per er erat at atio ion n n (H (H (HR R R 2. 2. 2 55 55 55)-)--a a a re e esu su sul lt lt w w whi hi ich ch h pe pe p r r rsis is ste ted d d ac ac acro ross ss ss t the e e s spe pe p c ct ctru u um m of patient age ge g . . Un Un Unli li like ke k p pri r r or or r s s stu tu t di di dies es e , , th th t is is s di di diff ff ffer er eren en nce ce ce w w was a o o obs bs bser er erve ve ved d d th h hro ro roug ug ugho ho hout ut u t the he he f f fol ol ollo lo ow-w up have not previously demonstrated a significantly lower risk of thromboembolism in patients treated with bioprostheses (versus those with mechanical valves on warfarin therapy). Despite a low perceived risk of stroke in patients with bioprostheses, its incidence remains high in this group. It is unclear whether this risk is concentrated within a group of patients who carry or develop traditional risk factors for ischemic stroke after AVR (e.g., atrial fibrillation or reduced LVEF); it is also unknown whether the benefits of vitamin K inhibition or alternative anticoagulation regimens (i.e., direct thrombin inhibitors or factor Xa inhibitors) would outweigh their risks in this cohort, especially given the demonstrated risk of hemorrhagic stroke (3.7% by 12 years) in those patients who were presumably treated with warfarin therapy in the setting of a mechanical valve prostheses.
Practical Applications
The results presented in this analysis demonstrate the complexities and trade-offs of selecting an aortic valve prosthesis in older patients. This decision is ultimately one that must be made in conjunction with the patient; however, examination of results from three important subgroups may help inform this discussion. First, among patients 70 years of age or older, bioprostheses offer at least equivalent survival to mechanical valves with a lower risk of stroke and
hemorrhage, yet the use of bioprostheses in these patients comes at the expense of a slightly higher absolute risk of both reoperation and endocarditis. Second, for patients between 65 and 69 years of age, mechanical valves are associated with a slightly lower long-term relative risk of mortality and a substantially lower risk (both absolute and relative) of reoperation when compared with bioprosthetic valves, yet the use of mechanical valves in this younger cohort carries an increased long-term risk of rehospitalization for hemorrhage and stroke. Finally, among older patients with renal failure, bioprostheses are associated with a lower long-term risk mechanical valve prostheses.
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prostheses tend to be used only in healthier elderly patients, the direction of this potential bias 
Conclusions
Among older individuals, the incidence of both mortality and valve-associated morbidities is high in the first 12 years after AVR. Mechanical valves are associated with improved late survival and long-term prosthesis durability; however, these gains are achieved at the cost of an increased incidence of bleeding and stroke among patients receiving mechanical valves. The comparative safety and effectiveness of prosthetic heart valves is highly dependent on patient age and underlying comorbidities, and the choice of an appropriate prosthesis remains complex. de depe pe pend nd nden ent t on on on p pa at tie e ent nt a a age ge e a at th th the e ti ti time me me o of f f im im mpl pl plan n nta ta t ti ti ion n n. Th Th Ther er ere ef efor or ore, e, e t the he hese se s r r res s sul ults ts ts s s sho ho h u ul uld d d no no ot be be viewed as ge gene ne nera ra r li li liza za zabl bl ble e e to o y y you ou o ng ng nger er e p p pat t tie ie i nt nt nts. s. s.
Ultimately, the most appropriate prosthesis for a given patient can only be determined through careful discussion between patients and their healthcare providers. The e e fu fu fund nd ndin in i g g or o orga ga ani ni niza zati tion on on h h had ad ad n no no r rol ol ole e in in in t t th he h desig gn 
